Venture Life Share Discussion Threads

[chester9] 04/6/2024 06:09

The business continues to perform well and our increased focus on promoting the VLG owned brands is delivering pleasing results, with an additional 35 new listings secured within UK retail since the beginning of the year. We remain confident about the outlook for the year ahead and our ability to deliver full year performance in line with management's expectations. Further commentary over first half trading will be provided as part of our usual business update in July."

[basem1] 03/6/2024 10:45

I would say that the chart is just playing out higher lows higher highs etc Given that we are worth 60p minimum it is no surprise.

[qs99] 03/6/2024 10:06

Couldn't see that AGM notice, thanks for posting. So tomorrow, wonder why it had stepped up, I've bought a few more as it hasn't moved for ages, fingers xd....DYOR

[basem1] 30/5/2024 12:33

Could Gelclair be a company maker in its own right Mid 60's coming here this year

[rivaldo] 30/5/2024 12:16

Cheers Celeritas, good news. Good to see the upward trend here continuing too.

[lammylover] 23/5/2024 05:45

NOTICE IS GIVEN to the holders of ordinary shares in Venture Life
Group plc (“the Company”) that the Annual General Meeting (“AGM”)
of the Company will be held at the offices of Simmons & Simmons LLP,
CityPoint, 1 Ropemaker Street, London, EC2Y 9SS on 4 June 2024 at
10:00a.m.

[mfhmfh] 23/5/2024 04:50

No RNS issued regarding date of AGM.

[sharw] 23/5/2024 00:08

What are you on about?

[mfhmfh] 22/5/2024 18:12

No AGM date/statement. Was on 22nd May last year.

[deanowls] 09/5/2024 08:30

What are the projected sales in the usa then?

[lammylover] 03/5/2024 09:34

Someone just sold 40,917 at 39.25p. Might be able to get these for a reasonable price?

[basem1] 03/5/2024 07:13

Dam it Nearly bought another 50,000 yesterday at 39.12 Now it has gone NT only at 39.5 on only 17000 buys Next leg up commencing guys

[rivaldo] 29/4/2024 09:03

Cavendish's latest research from earlier this month hasn't been posted here yet in detail.

They have a 68p target price, and they forecast 5.5p EPS this year rising to 6.9p EPS and then 7.9p EPS.

Here's some extracts:

"Strong organic growth; focus on EBITDA

Venture Life has reported FY23 results to December 2023, following the February trading update. Revenues grew 17% in the year to £51.4m (our est. £50.7m) and adjusted EBITDA was £11.6m (our est. £11.6m). Cash conversion was 85%, generating £9.8m of cash from operations. Cash generation and no M&A in 2023 allowed the company to de-lever, closing FY23 with net debt to adjusted EBITDA at 1.3x.

Management have focused on growth with three therapy areas generating double-digit revenue growth and online sales up +40%. Our extended forecasts anticipate increased investment, developing new products and expanding distribution channels to drive future revenue growth, with a focus on EBITDA and cash generation. We believe Venture Life has delivered strong organic performance in 2023 and anticipate on-going growth which could be complemented by re-starting the M&A strategy."

"Cash – The company generated cash from operations of £9.8m (FY22: £6.2m), indicating cash conversion of 85%. FCF for debt servicing was £4.8m, up strongly versus £2.8m in FY22. Strong cash generation and no M&A in 2023 allowed the company to deleverage, closing FY23 with net debt to adjusted EBITDA of 1.3x (FY22: 1.65x), which has subsequently fallen to 1.15x."

"Outlook – We note Venture Life’s stated commitment to improving EBITDA margins, that, while lowered in the near-term, are expected to benefit from marketing investment. This reflects a focus on profit and cash generation across all revenue streams, generally regardless of the differing gross margins. We expect this focus to support profit and cash growth for the business.

Investment thesis – Venture Life has delivered an organic 2023, demonstrating its ability to grow revenues and generate cash, allowing the company to de-leverage. We believe the company exited 2023 in excellent shape, noting a diverse product portfolio with further organic growth opportunities, available manufacturing capacity for expansion into new opportunities and a stronger balance sheet to re-engage its M&A strategy."

They also "expect the company to re-initiate its acquisition strategy during 2024 and beyond", and "as of the end of FY24E, based upon our forecasts of the current business, Venture Life would have £16m of the initial £30m RCF available, plus the potential to draw a further £20m".

Under different scenarios this could add between a further £2.5m-£7.5m of EBITDA to current forecasts.

[deanowls] 25/4/2024 13:58

I listened to a podcast yesterday undr the cosh with Nick Anderson who was a football who underwent chemo, he spoke about how bad his mouth was for one of the worst side effects.

[celeritas] 25/4/2024 13:30

I expect this Gelclair news will be picked up by other pharma's in other countries, the first of many.

[celeritas] 25/4/2024 13:28

What is ‘chemo mouth’ and could a brand new treatment offer relief?
18-Apr-2024 By Isabel Cameron

‘Chemo mouth’, otherwise known as oral mucositis, has emerged as the most significant adverse event in oncology, according to a National Comprehensive Cancer Network task force.

[rivaldo] 24/4/2024 07:58

Breaking upwards nicely now. Hopefully soon to attack the early '23 levels of 45p-46p and then to move on up to 60p or more.

[parttime] 23/4/2024 19:21

To be honest I thought the shares looked good value last year and bought my first tranche at 48p, somewhat bitter/sweet moments when you're adding at prices some 30% cheaper.

[thedudie] 23/4/2024 15:19

I thought the results, the presentation and the recent licensing news would have moved it into the 50p range already so maybe a tip is incoming. I think it is cheap.

The share price was higher than this last year but the company has been making good progress which suggests the peak this time should be higher!

[qs99] 23/4/2024 14:49

Tipped somewhere or is this on the back of the news above do we think?

[rivaldo] 23/4/2024 12:42

Good spot Cleritas, cheers.

[celeritas] 19/4/2024 13:55

Jaguar Health is expanding its focus to include cancer-related supportive care, with Gelclair being a foundational element in this strategy.